secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125332
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen Q3 revenue up 15% to $46.3M; net loss narrows to $17.1M; reiterates FY guidance
--------------------------------------------------------------------------------

- Net product revenue from roxadustat in China $46.2M, +57% YoY; total roxadustat net sales $96.6M, +25% YoY.
- Net loss $17.1M ($0.17 loss per share) vs $63.6M ($0.65) YoY; cash & equivalents $160M sufficient into 2026.
- Full-year guidance: total roxadustat net sales $330-350M; net product revenue $135-150M; cost plan substantially complete by year-end.
- Pamrevlumab trials in pancreatic cancer (mPDAC and LAPC) failed primary endpoints; pipeline focus shifts to FG-3246 ADC.
- FG-3246 Phase 2 combo study results expected 1H 2025; Phase 2 monotherapy trial starts Q1 2025; CIA approval decision early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/0000950170-24-125332-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/fgen-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125332

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer